PAPERS

ARTIGOS BRASILEIROS NA ÍNTEGRA

Artigos Autoria
Serum Levels of Infliximab and Anti-Infliximab Anti-bodies in Brazilian Patients with Crohn’s Disease Luis Eduardo Miani Gomes, Francesca Aparecida Ramos da Silva, Lívia Bitencourt Pascoal, Renato Lazarin Ricci, Guilherme Nogueira , Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, João José Fagundes, Raquel Franco Leal
Enviado por: Raquel Franco Leal
Role of diet and nutrition in inflammatory bowel disease Marina Moreira de Castro, Lívia Bitencourt Pascoal, Karine Mariane Steigleder, Beatriz Piatezzi Siqueira,
Ligiana Pires Corona, Maria de Lourdes Setsuko Ayrizono, Marciane Milanski, Raquel Franco Leal
Enviado por: Raquel Franco Leal
The role of chemokines and adipokines as biomarkers of Crohn’s disease activity: a systematic review of the literature Juliana Delgado Campos Mello, Luis Eduardo Miani Gomes, Julian Furtado Silva, Natalia Souza Nunes
Siqueira, Lívia Bitencourt Pascoal, Carlos Augusto Real Martinez, Maria de Lourdes Setsuko Ayrizono,
Raquel Franco Leal
Enviado por: Raquel Franco Leal
The Immunological Basis of Inflammatory Bowel Disease Francesca A. R. Silva, Bruno L. Rodrigues, Maria de Lourdes S. Ayrizono, and Raquel F. Leal
Enviado por: Raquel Franco Leal
Relationship among psychological well-being, resilience and coping with social and clinical features in Crohn’s disease patients Arlete Silva ACCIARI, Raquel Franco LEAL, Cláudio Saddy Rodrigues COY, Cristiana Corrrêa DIAS and Maria de Lourdes Setsuko AYRIZONO
Enviado por: Raquel Franco Leal
Pouchitis: insight into the pathogenesis and clinical aspects Leandro Minatel Vidal de Negreiros, Lívia Bitencourt Pascoal, Lívia Moreira Genaro, Julian Furtado Silva,
Bruno Lima Rodrigues, Michel Gardere Camargo, Carlos Augusto Real Martinez, Cláudio Saddy Rodrigues
Coy, Maria de Lourdes Setsuko Ayrizono, João José Fagundes, Raquel Franco Leal
Enviado por: Raquel Franco Leal
New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease Lívia Bitencourt Pascoal, Bruna Biazon Palma, Fabio Henrique Mendonça Chaim, Marina Moreira de Castro,
Tiago Andrade Damázio, Ana Paula Menezes de Freitas Franceschini, Marciane Milanski, Lício Augusto
Velloso, Raquel Franco Leal
Enviado por: Raquel Franco Leal
Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples Lívia Bitencourt Pascoala, Patrícia Brito Rodriguesa Lívia Moreira Genaro, Arilson Bernardo dos Santos Pereira Gomes, Daniel Augusto Toledo-Teixeira, Pierina Lorencini Parise, Karina Bispo-Dos-Santos, Camila Lopes Simeoni, Paula Veri Guimarães, Lucas Ildefonso Buscaratti, João Gabriel De Angeli Elston, Henrique Marques-Souza, Daniel Martins-de-Souza, Maria De Lourdes Setsuko Ayrizono, Lício Augusto Vellosog, José Luiz Proenca-Modena, Pedro Manoel Mendes Moraes-Vieira, Marcelo Alves Silva Mori, Alessandro Santos Farias, Marco Aurélio Ramirez Vinolo, and Raquel Franco Leal
Enviado por: Raquel Franco Leal
Intestinal paracoccidioidomycosis resembling Crohn’s disease in a teenager: a case report Elizete Aparecida Lomazi, Leandro Minatel Vidal de Negreiros, Pedro Vitor Veiga Silva Magalhães, Raquel de Castro Siqueira Togni, Nielce Maria de Paiva, Antonio Fernando Ribeiro and Raquel Franco Leal
Enviado por: Raquel Franco Leal
Ileal pouch of ulcerative colitis and familial adenomatous polyposis patients exhibit modulation of autophagy markers Nielce Maria Paiva, Lívia Bitencourt Pascoal, Leandro Minatel Vidal Negreiros, Mariana Portovedo, Andressa Coope, Maria de Lourdes Setsuko Ayrizono, Claudio Saddy Rodrigues Coy, Marciane Milanski & Raquel Franco Leal
Enviado por: Raquel Franco Leal
Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFα therapy Raquel Franco Leal, Núria Planell,Radhika Kajekar, Juan J Lozano, Ingrid Ordás, Isabella Dotti, Miriam Esteller, M Carme Masamunt,
Harsukh Parmar, Elena Ricart,Julián Panés, Azucena Salas
Enviado por: Raquel Franco Leal
Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study Natália Souza Nunes Siqueira, Livia Bitencourt Pascoal, Bruno Lima Rodrigues, Marina Moreira de Castro, Alan Sidnei Corrêa Martins, Dante Orsetti Silva Araújo, Luis Eduardo Miani Gomes, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal
Enviado por: Raquel Franco Leal
ER stress activation in the intestinal mucos abut not in mesenteric adipose tissue is associated with inflammation in Crohn’s disease patients Andressa Coope, Lívia Bitencourt Pascoal, José Diego Botezelli, Francesca Aparecida Ramos da Silva, Maria de Lourdes Setsuko Ayrizono, Bruno Lima Rodrigues, Marciane MilanskiID, Rita Barbosa Carvalho, João José Fagundes, Lício Augusto Velloso, Raquel Franco Leal
Enviado por: Raquel Franco Leal
Epidemiological profile and clinical characteristics of inflammatory bowel diseases in a Brazilian referral center Luiza Maria Pilau FUCILINI, Lívia Moreira GENARO, Daniela Cunha e SOUSA, Cláudio Saddy Rodrigues COY, Raquel Franco LEAL and Maria de Lourdes Setsuko AYRIZONO
Enviado por: Raquel Franco Leal
Endoplasmic Reticulum Stress in Colonic Mucosa of Ulcerative Colitis Patients Is Mediated by PERK and IRE1 Pathway Activation Bruno Lima Rodrigues , Isabella Dotti, Lívia Bitencourt Pascoal,Joseane Morari, Miriam Esteller, Andressa Coope, Maria de Lourdes Setsuko Ayrizono, Azucena Salas and Raquel Franco Leal
Enviado por: Raquel Franco Leal
Defective Apoptosis in Intestinal and Mesenteric Adipose Tissue of Crohn’s Disease Patients Cilene Bicca Dias, Marciane Milanski, Mariana Portovedo, Vivian Horita, Maria de Lourdes Setsuko Ayrizono, Núria Planell, Cláudio Saddy Rodrigues Coy, Lício Augusto Velloso, Luciana Rodrigues Meirelles, Raquel Franco Leal
Enviado por: Raquel Franco Leal
Crohn’s disease - treatment with biological medication Cyrla Zaltman, Heda Amarante, Marta Machado Brenner, Marcia Henriques Magalhaes Costa, Cristina Flores, Raquel Franco Leal Genoile Santana, Marco Zeroncio
Enviado por: Raquel Franco Leal
Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores Bruno Lima Rodrigues, Márcia Carolina Mazzaro, Cristiane Kibune Nagasako, Maria de Lourdes Setsuko
Ayrizono, João José Fagundes, Raquel Franco Leal
Enviado por: Raquel Franco Leal
Aspects Towards the Anastomotic Healing in Crohn’s Disease: Clinical Approach and Current Gaps in Research F.H.M. Chaim, L.M.V. Negreiros, K.M. Steigleder, N.S.N. Siqueira, L.M. Genaro, P.S.P. Oliveira, C.A.R. Martinez, M.L.S. Ayrizono, J.J. Fagundes and R.F. Leal
Enviado por: Raquel Franco Leal
Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach Lívia Moreira Genaro, Luís Eduardo Miani Gomes, Ana Paula Menezes de Freitas Franceschini, Hugo Dugolin Ceccato, Rafael Nascimento de Jesus, Amanda Pereira Lima, Cristiane Kibune Nagasako, João José Fagundes, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal
Enviado por: Raquel Franco Leal
Transcriptional and Molecular Pathways Activated in Mesenteric Adipose Tissue and Intestinal Mucosa of Crohn’s
Disease Patients
Andressa Coope, Lívia Bitencourt Pascoal, Francesca Aparecida Ramos da Silva,José Diego Botezelli,Maria de Lourdes Setsuko Ayrizono, Marciane Milanski,Michel Gardere Camargo, Núria Planell, Mariana Portovedo, Cilene Bicca Dias,João José Fagundes, and Raquel Franco Leal
Enviado por: Raquel Franco Leal
Impaired nutritional status in outpatients in remission or with active Crohn's disease e classified by objective endoscopic and imaging assessments Marina Moreira de Castro, Ligiana Pires Corona, Lívia Bitencourt Pascoal, Bruno Lima Rodrigues, Maria de Lourdes Setsuko Ayrizono,
Claudio Saddy Rodrigues Coy, Raquel Franco Leal, Marciane Milanski
Enviado por: Raquel Franco Leal
Risk factors for complications after ileocolonic resection for Crohn’s disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study Takayuki Yamamoto, Antonino Spinelli, Yasuo Suzuki, Rogerio Saad-Hossne, Fabio Vieira Teixeira, Idblan Carvalho de Albuquerque, Rodolff Nunes da Silva, Ivan Folchini de Barcelos, Ken Takeuchi, Akihiro Yamada, Takahiro Shimoyama, Lorete Maria da Silva Kotze, Matteo Sacchi, Silvio Danese and Paulo Gustavo Kotze
Enviado por: Dr. Fábio Vieira Teixeira
Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients Karoline Soares Garcia, Bianca Pocopetz Facas , Marta Brenner Machado, Fábio Vieira Teixeira, Luisa Avedano, Sanna Lönnfors, Rogério Saad Hossne, Laurent Peyrin-Biroulet and Natália Sousa Freitas Queiroz
Enviado por: Dr. Fábio Vieira Teixeira
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB) Ligia Yukie Sassaki , Daniela Oliveira Magro , Rogerio Saad‑Hossne , Julio Pinheiro Baima , Cristina Flores , Lucianna Motta Correia , Lívia Medeiros Soares Celani , Maria De Lourdes De Abreu Ferrari , Patricia Zacharias , Marley Ribeiro Feitosa , Carlos Henrique Marques Dos Santos , Manoel Alvaro De Freitas Lins Neto , Abel Botelho Quaresma , Sergio Figueiredo De Lima Junior , Graciana Bandeira Salgado De Vasconcelos , Ornella Sari Cassol , Arlene Dos Santos Pinto , Gustavo Kurachi, Francisco de Assis Goncalves Filho, Rodrigo Galhardi Gasparin , Thaísa Kowalski Furlan, Wilson Roberto Catapani , Cláudio Saddy Rodrigues Coy , Vivian De Souza Menegassi , Marilia Majeski Colombo , Renata de Sá Brito Fróes , Fabio Vieira Teixeira , Antonio Carlos Moraes , Genoile Oliveira Santana , José Miguel Luz Parente , Eduardo Garcia Vilela, Natália Sousa Freitas Queiroz and Paulo Gustavo Kotze on behalf of GEDIIB (Brazilian Study Group of IBD)
Enviado por: Dr. Fábio Vieira Teixeira
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease Pablo A. Olivera, Stephane Zuily, Paulo G. Kotze, Veronique Regnault, Sameer Al Awadhi, Peter Bossuyt, Richard B. Gearry, Subrata Ghosh, Taku Kobayashi, Patrick Lacolley, Edouard Louis, Fernando Magro, Siew C. Ng , Alfredo Papa, Tim Raine, Fabio V. Teixeira, David T. Rubin, Silvio Danese and Laurent Peyrin-Biroulet
Enviado por: Dr. Fábio Vieira Teixeira
Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review Abel Botelho Quaresma  , Fernanda da Silva Barbosa Baraúna , Fábio Vieira Teixeira, Rogério Saad-Hossne and Paulo Gustavo Kotze
Enviado por: Dr. Fábio Vieira Teixeira
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study Ramir Luan Perin, MD,*, Daniela Oliveira Magro, PhD,†, Adriana Ribas Andrade, MD,‡, Marjorie Argollo, MD,§, Nayara Salgado Carvalho, MD,§, , Adérson Omar Moura Cintra Damião, PhD,¶, Adriana Zanoni Dotti, MD,‖, , Sandro da Costa Ferreira, MD,**, Cristina Flores, PhD,††, Juliano Coelho Ludvig, MD,‡‡, Rodrigo Bremer Nones, MD,§§, Natalia Sousa Freitas Queiroz, PhD,¶¶, , Rogério Serafim Parra, MD,‖, Flavio Steinwurz, MD,‖‖, Fabio Vieira Teixeira, PhD,***, and , Paulo Gustavo Kotze, PhD†††
Enviado por: Dr. Fábio Vieira Teixeira
Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study Letícia Rodrigues de Souza 1,* , Daniela Oliveira Magro 2 , Fábio Vieira Teixeira 3 , Rogério Serafim Parra 4 , Eron Fábio Miranda 1 , Omar Féres 4 , Rogério Saad-Hossne 5 , Giedre Soares Prates Herrerias 5 , Renato Mitsunori Nisihara 6 , Claudio Saddy Rodrigues Coy 2 , Ligia Yukie Sassaki 5 and Paulo Gustavo Kotze 1,*
Enviado por: Dr. Fábio Vieira Teixeira
Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review Paulo Gustavo Kotze,* ,a Fox E. Underwood,‡ Aderson Omar Mourão Cintra Damião,§ Jose Geraldo P. Ferraz,k Rogerio Saad-Hossne,¶ Martin Toro,# Beatriz Iade,** Francisco Bosques-Padilla,‡‡ Fábio Vieira Teixeira,§§ Fabian Juliao-Banos,kk Daniela Simian,¶¶ Subrata Ghosh,## Remo Panaccione,k Siew C. Ng,*** and Gilaad G. Kaplan‡,a
Enviado por: Dr. Fábio Vieira Teixeira
Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey Natália Sousa Freitas Queiroz, Fábio Vieira Teixeira, Marina Pamponet Motta, Liliana Andrade Chebli, Adriano Akira Ferreira Hino, Camilla de Almeida Martins, Abel Botelho Quaresma, Alexandre Augusto de Paula da Silva, Adérson Omar Mourão Cintra Damião, Rogerio Saad-Hossne, Paulo Gustavo Kotze
Enviado por: Dr. Fábio Vieira Teixeira
A theoretical exploratory analysis on the risk of dysbiosis in individuals with inflammatory bowel diseases, using the DYS/FQM questionnaire Carolina Rodrigues, Wilson R Catapani
Enviado por: Dr. Wilson Roberto Catapani

Artigos Científicos | 2019

  • Outubro
  • Abril
  • Março

N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE1, Peyrin-Biroulet L1, Loftus EV Jr1, Danese S1, Colombel JF1, Törüner M1, Jonaitis L1, Abhyankar B1, Chen J1, Rogers R1, Lirio RA1, Bornstein JD1, Schreiber S1; VARSITY Study Group.

Abstract
BACKGROUND:
Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.

METHODS:
In a phase 3b, double-blind, double-dummy, randomized trial conducted at 245 centers in 34 countries, we compared vedolizumab with adalimumab in adults with moderately to severely active ulcerative colitis to determine whether vedolizumab was superior. Previous exposure to a tumor necrosis factor inhibitor other than adalimumab was allowed in up to 25% of patients. The patients were assigned to receive infusions of 300 mg of vedolizumab on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46 (plus injections of placebo) or subcutaneous injections of 40 mg of adalimumab, with a total dose of 160 mg at week 1, 80 mg at week 2, and 40 mg every 2 weeks thereafter until week 50 (plus infusions of placebo). Dose escalation was not permitted in either group. The primary outcome was clinical remission at week 52 (defined as a total score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe disease] and no subscore >1 [range, 0 to 3] on any of the four Mayo scale components). To control for type I error, efficacy outcomes were analyzed with a hierarchical testing procedure, with the variables in the following order: clinical remission, endoscopic improvement (subscore of 0 to 1 on the Mayo endoscopic component), and corticosteroid-free remission at week 52.

RESULTS:
A total of 769 patients underwent randomization and received at least one dose of vedolizumab (383 patients) or adalimumab (386 patients). At week 52, clinical remission was observed in a higher percentage of patients in the vedolizumab group than in the adalimumab group (31.3% vs. 22.5%; difference, 8.8 percentage points; 95% confidence interval [CI], 2.5 to 15.0; P = 0.006), as was endoscopic improvement (39.7% vs. 27.7%; difference, 11.9 percentage points; 95% CI, 5.3 to 18.5; P<0.001). Corticosteroid-free clinical remission occurred in 12.6% of the patients in the vedolizumab group and in 21.8% in the adalimumab group (difference, -9.3 percentage points; 95% CI, -18.9 to 0.4). Exposure-adjusted incidence rates of infection were 23.4 and 34.6 events per 100 patient-years with vedolizumab and adalimumab, respectively, and the corresponding rates for serious infection were 1.6 and 2.2 events per 100 patient-years.

CONCLUSIONS:
In this trial involving patients with moderately to severely active ulcerative colitis, vedolizumab was superior to adalimumab with respect to achievement of clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission. (Funded by Takeda; VARSITY ClinicalTrials.gov number, NCT02497469; EudraCT number, 2015-000939-33.).


N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE1, Sandborn WJ1, Panaccione R1, O'Brien CD1, Zhang H1, Johanns J1, Adedokun OJ1, Li K1, Peyrin-Biroulet L1, Van Assche G1, Danese S1, Targan S1, Abreu MT1, Hisamatsu T1, Szapary P1, Marano C1; UNIFI Study Group.

Abstract
BACKGROUND:
The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.

METHODS:
We evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy in patients with moderate-to-severe ulcerative colitis. A total of 961 patients were randomly assigned to receive an intravenous induction dose of ustekinumab (either 130 mg [320 patients] or a weight-range-based dose that approximated 6 mg per kilogram of body weight [322]) or placebo (319). Patients who had a response to induction therapy 8 weeks after administration of intravenous ustekinumab were randomly assigned again to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 12 weeks [172 patients] or every 8 weeks [176]) or placebo (175). The primary end point in the induction trial (week 8) and the maintenance trial (week 44) was clinical remission (defined as a total score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe disease] and no subscore >1 [range, 0 to 3] on any of the four Mayo scale components).

RESULTS:
The percentage of patients who had clinical remission at week 8 among patients who received intravenous ustekinumab at a dose of 130 mg (15.6%) or 6 mg per kilogram (15.5%) was significantly higher than that among patients who received placebo (5.3%) (P<0.001 for both comparisons). Among patients who had a response to induction therapy with ustekinumab and underwent a second randomization, the percentage of patients who had clinical remission at week 44 was significantly higher among patients assigned to 90 mg of subcutaneous ustekinumab every 12 weeks (38.4%) or every 8 weeks (43.8%) than among those assigned to placebo (24.0%) (P = 0.002 and P<0.001, respectively). The incidence of serious adverse events with ustekinumab was similar to that with placebo. Through 52 weeks of exposure, there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esophageal varices) and seven cases of cancer (one each of prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who received ustekinumab and no deaths and one case of cancer (testicular cancer) among 319 patients who received placebo.

CONCLUSIONS:
Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).

Saiba mais

Curr Pharm Des. 2019 Apr 5. doi:
10.2174/1381612825666190405141410. [Epub ahead of print]
JAK inhibition: the most promising agents in the IBD pipeline? Fernández-Clotet A, Castro-Poceiro J, Panés J.

Abstract
Under current therapeutic algorithms, half of the patients with moderate-severe ulcerative colitis or Crohn's disease fail in achieving a sustained remission. New drugs with different mechanisms of action are needed. After two decades of new drug avenues in inflammatory bowel disease dominated by the development of monoclonal antibodies, in recent years we are witnessing promising developments of small molecules for these conditions. Their intrinsic characteristics make them attractive compared to monoclonal antibodies based on their oral administration, short plasma half-life, lack of immunogenicity and predictable pharmacokinetics. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials. Tofacitinib has been the first JAKinhibitor approved for the treatment of ulcerative colitis. This review discusses the molecular aspects of the JAK-STAT pathway, its role in the pathogenesis of inflammatory bowel disease, and the rational use of JAK inhibitors in these conditions. The different compounds with JAKinhibitory activity tested are reviewed and provide an overview of recent evidence of clinical trials. Finally, we consider the positioning of these drugs in the treatment of inflammatory bowel diseases.


Saiba mais

Curr Pharm Des. 2019 Mar 13. doi:
10.2174/1381612825666190313140811. [Epub ahead of print]
IL-23 Blockers: Born to be First-line Biologic Agents in IBD?
Argollo MC, Allocca M, Furfaro F, Danese S.

Abstract
Over the past decades, the advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD. However, primary and more importantly, secondary loss of response to anti-TNF agents, is often observed. Thus, new treatment options have been actively explored and some have already been incorporated in the current clinical practice. Among the class of anti-cytokine agents, the anti-IL12/IL23 monoclonal antibodies (mAbs) have been first presented, in clinical practice, by the anti-p40 mAb ustekinumab in Crohn's disease (CD). More selective anti-IL23 agents (anti-p19) have shown efficacy and are being further developed, in contrast to agents inhibiting IL-17 downstream, which have failed in IBD clinical trials despite their clear efficacy in psoriasis.


Saiba mais

GAMEDII

Nas Redes Sociais

Facebook

Youtube

Instagram

Blog

CARTÃO PRIORIDADE

Cartão Prioridade

História em Quadrinhos

Clique para Download

QUERO ME CADASTRAR